Investor Relations


Featured Events

Johnson & Johnson Third Quarter 2014 Earnings Meeting and Webcast
October 14, 2014
8:30 AM ET


Stock Symbol JNJ
Current Price $107.78
Change $+0.74
Day High $108.18
Day Low $107.26
Volume 10,585,600
Trades 55,461
10/31/2014 4:03 PM
Minimum 20 mins delay.

Stock Transfer Agent
Computershare
1-800-328-9033
or
781-575-2718
outside the U.S. and Canada


Investing in Johnson & Johnson.

Johnson & Johnson has been a part of people's lives for 128 years and a valuable part of their investments for approximately 70 years. Founded in 1886, we listed our shares on the New York Stock Exchange for public investors in 1944.

During our history, we have built the most comprehensive base of health care businesses in the world, generating approximately 70 percent of our revenues from No. 1 or No. 2 global leadership positions in our respective markets.

Our consistent performance has enabled us to deliver an exceptional track record of growth that few, if any, companies can claim: 30 consecutive years of adjusted earnings increases; and 52 consecutive years of dividend increases. Over the last 10 years, Johnson & Johnson stock generated a 8.9 percent total return for investors compared to a 7.4 percent total return for the S&P 500.(1)



E-Delivery of Annual Meeting and Proxy Materials

Johnson & Johnson is dedicated to improving the health and well-being of people everywhere. To fulfill this goal, we must protect the environments in which we work and live. A healthy planet and a healthy community go hand in hand. With this in mind, we now offer electronic versions of all of our company publications like the Annual Report.


Click here for the Johnson & Johnson 2013 Annual Report
Click here for the Johnson & Johnson 2014 Proxy Statement
Click here for the Johnson & Johnson 2013 Digital Annual Report

You can do your part as well. By reducing the amount of printed shareholder materials you receive, you can help protect the environment while quickly receiving important shareholder documents. In addition, reducing the printing and mailing costs associated with more traditional delivery methods allows us to control expenses in the interest of delivering more value for all our shareholders.

Registered Johnson & Johnson shareholders can sign up for electronic delivery of our reports and publications. Please go to www.computershare-na.com/green or contact our transfer agent, Computershare, at 1-800-328-9033.

Beneficial (owned through a broker/bank) Johnson & Johnson shareholders can register for on-line delivery of materials by clicking here and following the easy directions to your account.


Investor News

October 22, 2014
Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production

October 20, 2014
IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenström's macroglobulinemia

October 17, 2014
European Commission Approves IMBRUVICATM in Two Forms of Blood Cancer

Investor Communications

October 14, 2014 at 8:30 AM ET
Johnson & Johnson Third Quarter 2014 Earnings Meeting and Webcast

Financial Quick Links

Johnson & Johnson Reports 2014 Third-Quarter Results

Sales of Key Products/Franchises Q3 2014

Reconciliation of Non-GAAP Financial Measures Q3 2014

5 Year Financial Review


1. Data source - Bloomberg